Skip to main content
| News

Versameb raises 6 million Swiss francs

17.07.2020

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Using revenues obtained from a seed financing round totaling 6 million Swiss francs, Versameb is planning to bring its VERSagile platform to the clinical development stage by the end of 2021, as detailed in a press release. Versameb has developed VERSagile in order to program mRNA sequences for improved therapeutic efficacy. To this end, a molecular algorithm developed by the Basel-based company is used. The molecules developed in this fashion are designed to be used in the areas of dermatology and oncology, as well in the field of myology, the study of muscle diseases.

The potential of the Versameb approach was recognized very early on by the investment and innovation promotion agency Basel Area Business & Innovation, which supported the company in 2017/18 by way of BaseLaunch, the organization’s biotech accelerator and incubator. Versameb has now set its sights on driving forward the development of the company. To this end, it has strengthened its management team with the addition of Klaas P. Zuideveld, who has been appointed Chief Development Officer (CDO). He will bring a “rare combination” of scientific excellence and management experience to the role, according to Friedrich Metzger, Co-Founder and CEO of Versameb, who was quoted in the press release.

With Versameb having already achieved important milestones with the VERSagile platform, Dr. Reinhard Ambros, Chairman of the Board of Versameb and former Head of the Novartis Venture Fund, is delighted to see “that the company is attracting excellent talent to perform on our strategic and operational goals and that it is enjoying strong support from its investors”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Basel still the most attractive small city for business in Europe
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Ariceum Therapeutics establishes subsidiary in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
RocketVax raises fresh capital
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

RocketVax raises fresh capital

The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...

Read More
Clinerion is now part of Citeline
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion is now part of Citeline

Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...

Read More
KUORI developing biodegradable plastics
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
1 2 3 32

Do you have a question? We'd like to hear from you.